{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:51:50Z","timestamp":1793386310124,"version":"4.5.0"},"reference-count":26,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"La Paz Institute for Health Research (IdiPAZ)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Interictal burden (IB), defined as the symptoms and impairments that occur between migraine attacks, including cognitive dysfunction, photophobia, and fatigue, is recognized as a significant determinant of quality of life in patients. A prospective observational study was conducted. Patients diagnosed with chronic migraine (CM) and under treatment with OnabotulinumtoxinA (OnabotA) according to the PREEMPT protocol (every 12 weeks) were assessed at baseline and at 3, 6, 9, and 12 months. The primary endpoint was to evaluate the change in the IB measured with the Migraine Interictal Burden Scale (MIBS-4) and in the monthly migraine days (MMD). The secondary endpoint was acute medication use. This single-center study included 150 patients (91.3% female; median age 44 years). MIBS-4 scores were decreased by 29.1% at 3 months (8.47 to 5.97) and by 41.6% at 12 months (to 4.86; p &lt; 0.001). IB-free status was achieved by 16 patients (10.7%). The most disabling baseline symptoms were photophobia (37%), fatigue (20%), and allodynia (18%), which reduced by 52%, 43%, and 39% at 12 months, respectively. MMD were reduced from 18.6 to 8.3 days at 12 months and triptan and analgesic intake decreased by 58.7% and 55.4%. OnabotA significantly reduced both IB and migraine frequency over 12 months, underscoring its relevance in CM management.<\/jats:p>","DOI":"10.3390\/toxins17090463","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:19:31Z","timestamp":1758021571000},"page":"463","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["OnabotulinumtoxinA Is an Effective Treatment for Reducing the Interictal Burden in Patients with Chronic Migraine: A Prospective Observational Study"],"prefix":"10.3390","volume":"17","author":[{"given":"Alejandro","family":"S\u00e1nchez-Huertas","sequence":"first","affiliation":[{"name":"Neurology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Camejo-Mas","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Garcia-Roldan","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Alonso-Castillo","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Pulido-Fraiz","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Higuera Ruiz de la Hermosa","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Portocarrero-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-6269","authenticated-orcid":false,"given":"Javier","family":"D\u00edaz-de-Ter\u00e1n","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"},{"name":"Hospital La Paz Institute for Health Research (IdiPAZ), Hospital Universitario La Paz, University Aut\u00f3noma de Madrid, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s10194-022-01467-z","article-title":"Measuring interictal burden among people affected by migraine: A descriptive survey study","volume":"23","author":"Hubig","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1032103","DOI":"10.3389\/fneur.2022.1032103","article-title":"The not so hidden impact of interictal burden in migraine: A narrative review","volume":"13","author":"Vincent","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","article-title":"Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study","volume":"11","author":"Matsumori","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/head.13914","article-title":"The Effect of Psychiatric Comorbidities on Headache-Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study","volume":"60","author":"Lipton","year":"2020","journal-title":"Headache J. Head Face Pain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","article-title":"Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of Life","volume":"84","author":"Buse","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","article-title":"A narrative review on the burden of migraine: When the burden is the impact on people\u2019s life","volume":"20","author":"Leonardi","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_7","first-page":"A89","article-title":"Development and validation of the Migraine Interictal Burden Scale (MIBS): A self-administered instrument for measuring the burden of migraine between attacks","volume":"68","author":"Buse","year":"2007","journal-title":"Neurology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Argyriou, A.A., Dermitzakis, E.v., Rikos, D., Xiromerisiou, G., Soldatos, P., Litsardopoulos, P., and Vikelis, M. (2024). Effects of OnabotulinumtoxinA on Allodynia and Interictal Burden of Patients with Chronic Migraine. Toxins, 16.","DOI":"10.3390\/toxins16020106"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/head.12346","article-title":"Onabotulinum A (Toxina Onabotul\u00ednica do tipo A, Botox\u00ae)","volume":"54","author":"Tepper","year":"2014","journal-title":"Headache"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Alonge, P., Brighina, F., Maccora, S., Pilati, L., di Marco, S., Ventimiglia, D., Maggio, B., Cutr\u00f2, I., Camarda, C., and Torrente, A. (2024). Beyond Pain: The Effects of OnabotulinumtoxinA Therapy on Sensitization and Interictal Symptoms in Chronic Migraine. Toxins, 16.","DOI":"10.3390\/toxins16050203"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gentile, D., Floresta, G., Patamia, V., Chiaramonte, R., Mauro, G.L., Rescifina, A., and Vecchio, M. (2020). An integrated pharmacophore\/docking\/3D-QSAR approach to screening a large library of products in search of future botulinum neurotoxin A inhibitors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249470"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1417831","DOI":"10.3389\/fneur.2024.1417831","article-title":"Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: A five-year retrospective study","volume":"15","author":"Madrigal","year":"2024","journal-title":"Front. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/head.14460","article-title":"Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study","volume":"63","author":"Lipton","year":"2023","journal-title":"Headache"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Barbanti, P., Orlando, B., Egeo, G., d\u2019Onofrio, F., Doretti, A., Messina, S., Autunno, M., Messina, R., Filippi, M., and Fiorentini, G. (2024). Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE\u2014The First Italian Multicenter, Prospective, Real-Life Study. Brain Sci., 14.","DOI":"10.3390\/brainsci14070672"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40263-024-01086-z","article-title":"Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review","volume":"38","author":"Hennessy","year":"2024","journal-title":"CNS Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/head.13843","article-title":"Dual Therapy with Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?","volume":"60","author":"Pellesi","year":"2020","journal-title":"Headache"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3331024241269735","DOI":"10.1177\/03331024241269735","article-title":"International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine","volume":"44","author":"Puledda","year":"2024","journal-title":"Cephalalgia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1296577","DOI":"10.3389\/fphar.2023.1296577","article-title":"Combination of anti-CGRP\/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: A retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety","volume":"14","author":"Corasaniti","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s10194-024-01925-w","article-title":"Combining treatments for migraine prophylaxis: The state-of-the-art","volume":"25","author":"Pellesi","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_20","unstructured":"Gonz\u00e1lez-Quintanilla, V., Evers, S., and Pascual, J. (2024). OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment. Medication Overuse Headache, Elsevier BV."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (StroBE) statement: Guidelines for reporting observational studies","volume":"335","author":"Pocock","year":"2007","journal-title":"BMJ"},{"key":"ref_22","unstructured":"(2018). Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache J. Head Face Pain"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/head.14958","article-title":"Validation of a Portuguese version of the four-item Migraine Interictal Burden Scale","volume":"65","author":"Pereira","year":"2025","journal-title":"Headache"},{"key":"ref_25","first-page":"e16340","article-title":"Characterization of the interictal burden: A global view of migraine","volume":"31","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/9\/463\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:21Z","timestamp":1760035581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/9\/463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["toxins17090463"],"URL":"https:\/\/doi.org\/10.3390\/toxins17090463","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}